AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23665648 — intervention group
Group type: EXPERIMENTAL
Intervention: Microthin DSAEK technique
Number of subjects: 13
Study 23665648 — intervention group
Group type: COMPARATOR
Intervention: Conventional DSAEK technique
Number of subjects: 13
Study 21864644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash and toothpaste based on triclosan, fluoride, and mineral salts
Number of subjects: 30
Study 21864644 — intervention group
Group type: COMPARATOR
Intervention: Salivary enzyme substitutes
Number of subjects: 30
Study 19412117 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 416
Study 19412117 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV
Number of subjects: 416
Study 19412117 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC
Number of subjects: 416
Study 19412117 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir
Number of subjects: 416
Study 19412117 — intervention group
Group type: EXPERIMENTAL
Intervention: indinavir
Number of subjects: 416
Study 19412117 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 416
Study 19412117 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine
Number of subjects: 416
Study 18165536 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG)
Number of subjects: 31
Study 18165536 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (non-IVIG)
Number of subjects: 31
Study 15447699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 728
Study 11321381 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-enriched preterm formula
Number of subjects: 23
Study 11321381 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm formula
Number of subjects: 23
Study 11321381 — intervention group
Group type: COMPARATOR
Intervention: Expressed breast milk
Number of subjects: 23
Study 9725477 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ipriflavone tablets three times daily
Number of subjects: 12
Study 9725477 — intervention group
Group type: COMPARATOR
Intervention: 300 mg Scherer capsules twice daily
Number of subjects: 12
Study 7975835 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccine (5 infants)
Number of subjects: 41
Study 7975835 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose vaccine (18 infants)
Number of subjects: 41
Study 7975835 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 infants)
Number of subjects: 41
Study 2658898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous porcine intestinal mucosal heparin
Number of subjects: 193
Study 2658898 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous porcine intestinal mucosal heparin
Number of subjects: 193
Study 2658898 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine intestinal mucosal heparin (both routes)
Number of subjects: 193
Study 4976123 — intervention group
Group type: EXPERIMENTAL
Intervention: Trasicor (beta-adrenergic blocking drug)
Number of subjects: 18
Study 4976123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31285738 — intervention group
Group type: EXPERIMENTAL
Intervention: Single strain probiotics, once daily for fourteen days
Number of subjects: 17
Study 31285738 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed strain probiotics, once daily for fourteen days
Number of subjects: 17
Study 31285738 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study 28341918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 49
Study 25423653 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (Hoehn & Yahr stage 2)
Number of subjects: 36
Study 25423653 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 24601169 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day therapy with omeprazole (20 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicilline (1000 mg b.i.d.)
Number of subjects: 105
Study 24601169 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day therapy with omeprazole (20 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicilline (1000 mg b.i.d.)
Number of subjects: 105
Study 24601169 — intervention group
Group type: COMPARATOR
Intervention: Both 7-day and 10-day therapies
Number of subjects: 105
Study 24601169 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 105
Study 20594551 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH alone (group 1)
Number of subjects: 98
Study 20594551 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH with Ganirelix when the leading follicle was ≥13 mm (group 2)
Number of subjects: 98
Study 20594551 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH with Ganirelix from the beginning of stimulation (group 3)
Number of subjects: 98
Study 18494346 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick flap group (160-microm flap)
Number of subjects: 28
Study 18494346 — intervention group
Group type: COMPARATOR
Intervention: Thin flap group (110-microm flap)
Number of subjects: 28
Study 15261932 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg irbesartan (IRB)
Number of subjects: 48
Study 15261932 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril (ENAL)
Number of subjects: 48
Study 15261932 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 48
Study 11600825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 750 mg tid + ZDV 200 mg tid + 3TC 150 mg bid
Number of subjects: 297
Study 11600825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 500 mg tid + ZDV 200 mg tid + 3TC 150 mg bid
Number of subjects: 297
Study 11600825 — intervention group
Group type: COMPARATOR
Intervention: ZDV 200 mg tid + 3TC 150 mg bid + placebo
Number of subjects: 297
Study 9636854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg once daily following a 400 mg loading dose on day 1)
Number of subjects: 329
Study 9636854 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (1 g oral dose three times daily)
Number of subjects: 329
Study 9636854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 329
Study 8082507 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodiol, 1200 mg/day
Number of subjects: 22
Study 8082507 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 8082507 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodiol
Number of subjects: 22
Study 8082507 — intervention group
Group type: EXPERIMENTAL
Intervention: open-label ursodiol
Number of subjects: 22
Study 2721115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 83
Study 2721115 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-smokers
Number of subjects: 83
Study 30944045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU)
Number of subjects: 93
Study 30944045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 30503128 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-warming culture for 1 hour (Group A)
Number of subjects: 162
Study 30503128 — intervention group
Group type: COMPARATOR
Intervention: Post-warming culture for 18 hours (Group B)
Number of subjects: 162
Study 27666738 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified treatment strategy
Number of subjects: 0
Study 27666738 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 24368437 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D₃/d
Number of subjects: 328
Study 24368437 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D₃/d
Number of subjects: 328
Study 24368437 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D₃/d
Number of subjects: 328
Study 24368437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 22289903 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative IABP starting at 12 hours (12T)
Number of subjects: 230
Study 22289903 — intervention group
Group type: COMPARATOR
Intervention: Preoperative IABP starting at 2 hours (2T)
Number of subjects: 230
Study 21336428 — intervention group
Group type: COMPARATOR
Intervention: Diet I (low fat) in control group
Number of subjects: 162
Study 21336428 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet I (low fat) in NAFLD group
Number of subjects: 162
Study 21336428 — intervention group
Group type: COMPARATOR
Intervention: Diet II (low carbohydrate) in control group
Number of subjects: 162
Study 21336428 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet II (low carbohydrate) in NAFLD group
Number of subjects: 162
Study 19137905 — intervention group
Group type: EXPERIMENTAL
Intervention: Estomine‐zee (escitalopram oxalate 10 mg and clonazepam 0.5 mg)
Number of subjects: 24
Study 19137905 — intervention group
Group type: COMPARATOR
Intervention: Commercially available formulation (escitalopram oxalate 10 mg and clonazepam 0.5 mg)
Number of subjects: 24
Study 15913460 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralised information resource for clinical trials
Number of subjects: 0
Study 15913460 — intervention group
Group type: EXPERIMENTAL
Intervention: Database containing standardised information for each trial
Number of subjects: 0
Study 15913460 — intervention group
Group type: EXPERIMENTAL
Intervention: Access via the Internet
Number of subjects: 0
Study 15913460 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of a centralised information resource
Number of subjects: 0
Study 11277446 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotic aftereffect (1-kHz adapting stimulus)
Number of subjects: 2
Study 11277446 — intervention group
Group type: EXPERIMENTAL
Intervention: Interotic aftereffect (adapting 1 ear and testing the other ear)
Number of subjects: 2
Study 11277446 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptation control condition
Number of subjects: 2
Study 9517277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin eardrops
Number of subjects: 60
Study 9517277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin eardrops
Number of subjects: 60
Study 9517277 — intervention group
Group type: COMPARATOR
Intervention: Placebo eardrops
Number of subjects: 60
Study 8038980 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane followed by propofol infusion (ISO‐PRO group)
Number of subjects: 60
Study 8038980 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia only (ISO group)
Number of subjects: 60
Study 3058135 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodropropizine
Number of subjects: 174
Study 3058135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 3058135 — intervention group
Group type: COMPARATOR
Intervention: Morclofone
Number of subjects: 174
Study 3058135 — intervention group
Group type: COMPARATOR
Intervention: Cloperastine
Number of subjects: 174
Study 30987852 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV F subunit vaccine with aluminum hydroxide adjuvant
Number of subjects: 0
Study 30987852 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV F subunit vaccine with MF59 adjuvant
Number of subjects: 0
Study 30987852 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV F subunit vaccine without adjuvant
Number of subjects: 0
Study 30987852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27788579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat
Number of subjects: 32
Study 27788579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25226273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion containing 10% fish oil
Number of subjects: 159
Study 25226273 — intervention group
Group type: COMPARATOR
Intervention: Fish oil-free lipid emulsion
Number of subjects: 159
Study 23996211 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 24
Study 21050695 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-hour communication skills course based on the Four Habits model
Number of subjects: 72
Study 21050695 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 72
Study 19850786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole granules with apple juice orally
Number of subjects: 25
Study 19850786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole granules with apple juice via nasogastric tube
Number of subjects: 25
Study 19850786 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole granules with applesauce orally
Number of subjects: 25
Study 18330097 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEM)
Number of subjects: 5
Study 18330097 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery (RS)
Number of subjects: 5
Study 14685005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimagedine 150 mg
Number of subjects: 690
Study 14685005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimagedine 300 mg
Number of subjects: 690
Study 14685005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study 14685005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimagedine (both doses)
Number of subjects: 690
Study 11298092 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MMI
Number of subjects: 71
Study 11298092 — intervention group
Group type: COMPARATOR
Intervention: 150 mg PTU
Number of subjects: 71
Study 9598512 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined orchiectomy and radiotherapy
Number of subjects: 91
Study 9598512 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 91
Study 7884369 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 347
Study 29426811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy
Number of subjects: 26
Study 29426811 — intervention group
Group type: COMPARATOR
Intervention: Excision followed by brachytherapy
Number of subjects: 26
Study 29426811 — intervention group
Group type: COMPARATOR
Intervention: Excision with corticosteroid injections
Number of subjects: 26
Study 26377167 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical pacing
Number of subjects: 21
Study 26377167 — intervention group
Group type: EXPERIMENTAL
Intervention: Outflow tract pacing
Number of subjects: 21
Study 24750284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 300 μg s.c. t.i.d.
Number of subjects: 9
Study 24750284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22314891 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 197
Study 22314891 — intervention group
Group type: COMPARATOR
Intervention: TVT-S H
Number of subjects: 197
Study 22314891 — intervention group
Group type: COMPARATOR
Intervention: TVT-S U
Number of subjects: 197
Study 20657263 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Disability Index
Number of subjects: 165
Study 20657263 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Functional Scale
Number of subjects: 165
Study 20657263 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Pain Rating Scale
Number of subjects: 165
Study 18172860 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 1616
Study 18172860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG)
Number of subjects: 1616
Study 18172860 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione (Delta4-A)
Number of subjects: 1616
Study 18172860 — intervention group
Group type: EXPERIMENTAL
Intervention: 3alpha-androstanediol glucuronide (3alpha-diolG)
Number of subjects: 1616
Study 16980867 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted lipoplasty
Number of subjects: 25
Study 16980867 — intervention group
Group type: COMPARATOR
Intervention: Suction-assisted lipoplasty
Number of subjects: 25
Study 14610472 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP -654
Number of subjects: 707
Study 14610472 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP +46
Number of subjects: 707
Study 14610472 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP +523
Number of subjects: 707
Study 14610472 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes of B2AR variants
Number of subjects: 707
Study 11302008 — intervention group
Group type: EXPERIMENTAL
Intervention: Berry group (100 g of deep-frozen berries daily for 8 weeks)
Number of subjects: 60
Study 11302008 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement group (100 mg of alpha-tocopherol and 500 mg of ascorbic acid daily)
Number of subjects: 60
Study 11302008 — intervention group
Group type: COMPARATOR
Intervention: Control group (500 mg of calcium gluconate daily)
Number of subjects: 60
Study 11302008 — intervention group
Group type: EXPERIMENTAL
Intervention: Berry group (80 g of each of the three berries in one go for short-term experiment)
Number of subjects: 60
Study 8635703 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection therapy (adrenaline and polidocanol)
Number of subjects: 104
Study 8635703 — intervention group
Group type: COMPARATOR
Intervention: Heater probe thermocoagulation (10F probe, at setting of 30 J)
Number of subjects: 104
Study 1425135 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir with corticosteroids
Number of subjects: 0
Study 1425135 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir alone
Number of subjects: 0
Study 1425135 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir ointment
Number of subjects: 0
Study 1425135 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Acyclovir
Number of subjects: 0
Study 3883972 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol hydrochloride (0.5% and 1%)
Number of subjects: 141
Study 3883972 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate (0.5%)
Number of subjects: 141
Study 30478992 — intervention group
Group type: COMPARATOR
Intervention: Fasting glucose levels categorized as <6.1 mmol/l (reference), 6.1-7.0 mmol/l (2nd), ≥7.0 mmol/l (3rd)
Number of subjects: 0
Study 30478992 — intervention group
Group type: COMPARATOR
Intervention: Self-reported diabetes
Number of subjects: 0
Study 30439313 — intervention group
Group type: EXPERIMENTAL
Intervention: Venturi combined with MR850 device active warm and humid oxygen therapy
Number of subjects: 80
Study 30439313 — intervention group
Group type: COMPARATOR
Intervention: Ordinary flow device and warm and humid exchanger (artificial nose, HME) passive humid oxygen therapy
Number of subjects: 80
Study 26252574 — intervention group
Group type: EXPERIMENTAL
Intervention: D-mix (3 g/dose)
Number of subjects: 10
Study 26252574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24925605 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate frog incentive
Number of subjects: 137
Study 24925605 — intervention group
Group type: COMPARATOR
Intervention: No chocolate frog incentive (Control)
Number of subjects: 137
Study 23255845 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng (KRG)
Number of subjects: 100
Study 23255845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19966175 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg twice daily)
Number of subjects: 42
Study 19966175 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone (Control)
Number of subjects: 42
Study 19966175 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (in patients with prolonged baseline QTc >440 ms)
Number of subjects: 42
Study 19966175 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (in patients with normal baseline QTc)
Number of subjects: 42
Study 19966175 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 42
Study 17593236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 441
Study 17593236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 15800664 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan-based antihypertensive treatment
Number of subjects: 0
Study 15800664 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 11916549 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) with 70 Gy in 7 weeks, 2 Gy per fraction, daily dose of 6 mg/m² cisplatin
Number of subjects: 53
Study 11916549 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fractionation (MFD) with three fractions of 1.6 Gy per day, daily dose of 10 mg/m² cisplatin
Number of subjects: 53
Study 9577904 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 50 mg i.v.
Number of subjects: 18
Study 9577904 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg i.v.
Number of subjects: 18
Study 9577904 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg i.v.
Number of subjects: 18
Study 9577904 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study 7897458 — intervention group
Group type: EXPERIMENTAL
Intervention: New antidepressant drugs
Number of subjects: 0
Study 7897458 — intervention group
Group type: COMPARATOR
Intervention: Older alternatives
Number of subjects: 0
Study 2678308 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CPT) 50 mg + hydrochlorothiazide (HCTZ) 15 mg
Number of subjects: 30
Study 2678308 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 25 mg alone
Number of subjects: 30
Study 345489 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of LH-RH
Number of subjects: 0
Study 345489 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of LH-RH
Number of subjects: 0
Study 345489 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH in combination with human menopausal gonadotrophins (HMG)
Number of subjects: 0
Study 31062282 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 72
Study 31062282 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 72
Study 31062282 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 72
Study 27981366 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 75 or FEC 100
Number of subjects: 0
Study 27981366 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere
Number of subjects: 0